Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial
Clayton AH, Althof SE, Kingsberg S, et al.
Womens Health, 2016 · n = 327
Key finding
Bremelanotide 1.75mg significantly improved sexual desire scores and reduced sexually related distress, establishing the dose for Phase 3.
Summary
Phase 2 dose-finding RCT establishing 1.75mg as optimal dose. Bremelanotide significantly increased desire and reduced distress in premenopausal women with HSDD.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on PT-141
Comparison of PT-141 and Flibanserin for Female Sexual Desire Disorder: An Indirect Treatment Comparison
Sexual Medicine Reviews · 2022 · Review
Blood Pressure and Cardiovascular Effects of Bremelanotide in Hypertensive Versus Normotensive Women
Journal of Sexual Medicine · 2021 · Human RCT
Long-Term Safety and Efficacy of Bremelanotide: 1-Year Extension Study in Women with HSDD
The Journal of Sexual Medicine · 2021 · Human Pilot
RECONNECT-1: A Randomized Controlled Trial of Bremelanotide for Female Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
RECONNECT-2: Phase 3 Trial of Bremelanotide in Premenopausal Women with Generalized Hypoactive Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT